Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.67) by $0.19, Briefing.com reports. The firm had revenue of $0.68 million during the quarter. During the same period last year, the firm earned ($0.79) earnings per share. The business’s quarterly revenue was up 518.2% compared to the same quarter last year.

Shares of Alder BioPharmaceuticals (NASDAQ ALDR) opened at 9.20 on Wednesday. The stock’s 50 day moving average is $12.91 and its 200-day moving average is $18.65. The stock’s market cap is $463.77 million. Alder BioPharmaceuticals has a 1-year low of $9.15 and a 1-year high of $36.48.

In related news, Director Stephen M. Dow purchased 25,000 shares of the business’s stock in a transaction dated Tuesday, July 18th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 10.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc increased its position in shares of Alder BioPharmaceuticals by 2.6% in the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 400 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Alder BioPharmaceuticals by 1.5% in the fourth quarter. Teachers Advisors LLC now owns 76,809 shares of the biopharmaceutical company’s stock worth $1,598,000 after buying an additional 1,171 shares in the last quarter. Baird Financial Group Inc. increased its position in shares of Alder BioPharmaceuticals by 7.9% in the first quarter. Baird Financial Group Inc. now owns 18,441 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 1,349 shares in the last quarter. Swiss National Bank increased its position in shares of Alder BioPharmaceuticals by 2.6% in the first quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock worth $1,380,000 after buying an additional 1,700 shares in the last quarter. Finally, American International Group Inc. increased its position in shares of Alder BioPharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 28,849 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 1,910 shares in the last quarter. Institutional investors and hedge funds own 82.44% of the company’s stock.

A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC set a $36.00 price objective on shares of Alder BioPharmaceuticals and gave the company a “buy” rating in a report on Monday, July 17th. Aegis reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Alder BioPharmaceuticals in a report on Wednesday, July 5th. ValuEngine cut shares of Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, June 29th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and issued a $51.00 price objective on shares of Alder BioPharmaceuticals in a report on Wednesday, June 28th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $35.00.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/alder-biopharmaceuticals-inc-aldr-issues-quarterly-earnings-results.html.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.